IGF-1 DES
A naturally occurring form of IGF-1 missing its first three amino acids, isolated from bovine colostrum and human brain in the 1980s. Its roughly tenfold potency advantage is a cell-culture figure — in animals it is closer to 2.5-fold — and the research-chemical market sells it as a site-injection muscle peptide on a localization claim that has never been tested in humans. In the one head-to-head animal comparison it was the most hypoglycaemic of the IGF-1 analogues tested.
IGF-1 DES is a natural variant of the growth factor IGF-1 with three amino acids clipped off one end, which lets it slip past the carrier proteins that normally hold IGF-1 inactive. Bodybuilders inject it into a specific muscle hoping to grow that muscle, but no human study has ever tested whether that works. The thing most worth knowing is that in the one head-to-head animal comparison, DES lowered blood sugar more than every other IGF-1 analogue tested, LR3 included.
What is IGF-1 DES?
IGF-1 DES — properly des(1-3)IGF-1 — is a naturally occurring truncated form of insulin-like growth factor 1, missing the N-terminal tripeptide Gly-Pro-Glu. It is not a designed analogue: it was purified from bovine colostrum and from human fetal and adult brain in the mid-1980s, and probably arises from post-translational cleavage of IGF-1. Three claims define how it is sold, and each needs qualifying. The first is potency. The review dedicated to this molecule puts it at about tenfold more potent than IGF-1 at stimulating hypertrophy and proliferation of cultured cells — a cell-culture figure. Given to animals, that advantage shrinks: in dexamethasone-treated rats, des(1-3)IGF-1 and LR3 were approximately 2.5-fold more potent than IGF-1 on weight gain and nitrogen retention. The tenfold number is real and it is not the in-vivo number. The second is binding. DES is routinely described as having essentially no affinity for the IGF binding proteins. Measured directly on a biosensor, it binds IGFBP-3 with 25-fold lower affinity than IGF-1 — a shift from a Kd of 0.23 nM to roughly 5.7 nM, which is much weaker binding but still high-affinity binding, not absence. The near-total loss is also species-specific: variants that bind extremely weakly in rat plasma bind appreciably in sheep, human, pig and chicken plasma, and much of the foundational DES pharmacology was done in rats. The third is the half-life. The widely repeated figure of 20 to 30 minutes has no identifiable source. What has actually been measured is clearance: in rats, des(1-3)IGF-1 cleared at 4.59 mL/min per kg against 1.20 for IGF-1, with a larger steady-state volume of distribution (461 versus 167 mL/kg). Faster than IGF-1, certainly — but an antidoping study detected unchanged des(1-3)IGF-1 in rats up to 24 hours after a single intramuscular dose, which is hard to reconcile with a half-life of half an hour.
What IGF-1 DES Is Investigated For
IGF-1 DES is used almost exclusively in the bodybuilding and research-chemical space for site-specific muscle growth at the injection site, with faster clearance and reduced IGFBP binding providing the rationale for its localized positioning. The strongest evidence is biochemical — near-complete loss of IGFBP binding is well-characterized, and IGF-1R signaling (PI3K/Akt/mTOR, Ras/MAPK) is one of the best-understood growth factor pathways. Beyond that, the human evidence is essentially absent: no clinical trials for any indication, no dose-response data, and no human imaging work to validate the central 'differential local hypertrophy' claim. Community dosing (20–75 mcg IM per site) rests on rodent extrapolation, and an antidoping laboratory that analysed black-market IGF-1 analogue products reported abundant signs of lower quality and oxidised peptide forms. One widely repeated safety claim about this molecule is not merely unsupported but inverted. DES is commonly presented as the safer of the two research IGF-1 analogues on hypoglycaemia, because it clears faster than LR3. The only study that compared them directly found the opposite. In pigs given five IGF-1 variants, acute hypoglycaemic potency ran in the order IGF-1 < long-IGF-1 < R3IGF-1 approximately LR3IGF-1 < des(1-3)IGF-1 — DES highest of the five — and the variants as a class suppressed glucose for much longer than IGF-1, with four- to eight-fold greater cumulative hypoglycaemia over four hours. The authors concluded that despite more rapid clearance from the circulation, the low-IGFBP-affinity variants show proportionately superior potency for sustained hypoglycaemic action. Faster clearance does not mean shorter glucose lowering, and localized does not mean systemically inactive.
History & Discovery
Des(1-3) IGF-1 — the 'DES' in the common name refers to the deletion of the first three N-terminal amino acids Gly-Pro-Glu — was first identified as a naturally occurring IGF-1 variant isolated from bovine colostrum and later detected in the human central nervous system. The tripeptide Gly-Pro-Glu that is cleaved off is itself neuroactive, and early neuroscience work by groups including Peter Gluckman in New Zealand characterized both the parent truncated peptide and the released N-terminal fragment as bioactive in their own right. The DES variant's key pharmacologic property, characterized across multiple groups including the Ballard/CSIRO program in Adelaide and aligning with the broader IGF-1 biology program of Derek Le Roith, is roughly an order-of-magnitude greater potency at IGF-1R compared with native IGF-1, attributable almost entirely to near-complete loss of IGFBP binding. Synthetic DES IGF-1 followed native-identification into the research-reagent market in the 1990s as a cell-culture tool and into whole-animal studies of localized versus systemic IGF-1 signaling. Unlike IGF-1 LR3, DES was never engineered as a long-acting depot — the short half-life (tens of minutes) is intrinsic to the truncation. Bodybuilding-market adoption arrived in the 2000s with the specific positioning as a 'site-injection' peptide for localized muscle growth, in contrast with LR3's systemic anabolic framing. Human therapeutic development never occurred.
How It Works
IGF-1 DES is a concentrated, fast-acting version of the body's growth signal. Because it works so quickly and locally, it can target specific muscles when injected directly into them.
Des(1-3)IGF-1 lacks the N-terminal tripeptide Gly-Pro-Glu, and that tripeptide is precisely the region the IGF binding proteins grip. Removing it reduces IGFBP-3 affinity 25-fold by direct biosensor measurement — from a Kd of 0.23 nM to roughly 5.7 nM — which is a large shift and not the abolition the popular account describes. The consequence is that a greater fraction of any dose circulates free and available to the type 1 IGF receptor, and that is where the potency advantage comes from. The evidence that the advantage is pharmacokinetic rather than pharmacodynamic is unusually direct. An early comparison found the destripeptide derivative roughly seven times more potent than IGF-1 in a protein-synthesis bioassay while showing no increased ability to compete for IGF-1 binding to L6 myoblasts. The receptor does not prefer DES. More DES simply reaches it. Downstream the signalling is ordinary IGF-1R biology: PI3K/Akt/mTOR driving protein synthesis, Ras/MAPK/ERK driving proliferation. In mice, des IGF-1 increased Akt-1 phosphorylation at Ser473 in both skeletal and cardiac muscle, with the p70 S6K response seen in young animals and absent in aged ones — the anabolic response is not age-invariant. The same experiment found no change in plasma insulin or IGF-1 but a roughly 50% fall in plasma glucose, which is the clearest single demonstration that an injected dose acts systemically. Two caveats bound all of this. Species first: the near-absent IGFBP binding that underpins the potency story is most extreme in rat plasma, and the same variants bind appreciably in sheep, human, pig and chicken plasma. Second, clearance is not duration of effect. Rat plasma clearance is roughly fourfold faster than IGF-1, yet unchanged des(1-3)IGF-1 was detectable up to 24 hours after a single intramuscular injection, and in pigs the low-IGFBP-affinity variants suppressed glucose over a much longer period than IGF-1 despite clearing faster. A short plasma residence confines neither the drug nor its effects to the injection site.
Evidence Snapshot
Human Clinical Evidence
None. There is no published clinical trial of des(1-3)IGF-1 for any indication, no human pharmacokinetic study, and no registered trial — ClinicalTrials.gov searches by intervention name return nothing, while the approved recombinant IGF-1 mecasermin returns many. Every human exposure happens outside medical supervision through research-chemical channels, with no systematic safety surveillance. The compound does appear in the antidoping literature, where detection methods have been validated precisely because it circulates on the black market.
Animal / Preclinical
Moderate, and considerably older than the marketing implies — most of it is from the late 1980s and 1990s. Anabolic effects are established in catabolic rodent models: reversal of dexamethasone-induced catabolism at roughly 2.5-fold the potency of IGF-1, and increased weight gain, nitrogen retention and muscle protein synthesis in diabetic rats. Muscle signalling work in mice shows Akt-1 activation in skeletal and cardiac tissue with an age-dependent p70 S6K response. Two of the neurological papers this page cites are negative results for the truncated peptide rather than positive ones. The dedicated review notes the in-vivo anabolic effect is most evident in gut tissue rather than muscle, which is not what the site-injection market assumes.
Mechanistic Rationale
Strong for the receptor biology, weaker for the specific claims made about this molecule. IGF-1R signalling is among the best-characterised growth factor pathways, and the reason DES is more potent is unusually well established: it is a binding-protein escape effect rather than a receptor effect, shown by higher bioassay potency with no increase in receptor competition. What the mechanism does not support is localization. Nothing about faster plasma clearance confines activity to an injection site, the measured systemic glucose effect contradicts it, and the IGFBP escape that drives the whole pharmacology is markedly smaller outside the rat.
Research Gaps & Open Questions
What the current literature has not yet settled about IGF-1 DES:
- 01No human clinical trials of DES IGF-1 for any indication — all human exposure is off-label via research-chemical channels without systematic safety surveillance.
- 02Actual site-specificity in humans. The localized-growth claim central to this compound's market positioning rests on fast clearance, but no human study has quantified local versus systemic IGF-1R activation after an intramuscular dose — and the mouse data showing a roughly 50% fall in plasma glucose argue that a meaningful systemic fraction exists.
- 03Human pharmacokinetics of des(1-3)IGF-1, which have never been measured. The widely circulated 20-to-30-minute half-life has no identifiable source; what exists is rat plasma clearance (4.59 mL/min per kg versus 1.20 for IGF-1) and the detection of unchanged peptide 24 hours after intramuscular dosing in rats. Neither gives a human half-life.
- 04How much IGFBP escape a human actually gets. The near-absent binding that underpins the potency story is largely a rat finding, and the same variants bind appreciably in sheep, human, pig and chicken plasma. The 25-fold reduction in IGFBP-3 affinity measured on a biosensor is the most defensible number, and it is a reduction rather than an abolition.
- 05Long-term local tissue effects — repeated IM injection of a mitogenic peptide into the same muscle is biologically plausible to induce fibrosis, chronic low-grade inflammation, or fibroblast dysregulation; no systematic imaging or histologic human study exists.
- 06Dose-response for hypertrophy versus adverse effects — the 20–75 mcg community range is not anchored in any human dose-ranging study; minimum effective and maximum tolerated doses are uncharacterized, and the dose at which hypoglycemia becomes clinically significant in a human is unknown.
- 07Cancer-risk impact of episodic supraphysiologic IGF-1R activation — the epidemiology linking IGF-1 to cancer is chronic-exposure data, and the implications of repeated short pulses in muscle tissue are unquantified.
- 08Supply-chain integrity — DES, LR3, and native IGF-1 are mislabeled across the research-chemical market; identity and purity assurance is not pharmaceutical-grade.
Forms & Administration
Supplied as a lyophilised powder by research-chemical vendors, labelled not for human use, and reconstituted in bacteriostatic water. Community practice is intramuscular injection into the belly of a trained muscle, in the range described under Dosing, timed around training. There is no approved product, no pharmaceutical formulation and no established human dose. The only IGF-1 product with a marketing authorisation is mecasermin (Increlex), recombinant full-length IGF-1 — a different molecule, still marketed by Ipsen. An antidoping analysis of black-market IGF-1 analogue products found abundant signs of lower quality and oxidised peptide forms, so identity and purity should not be assumed. All injectable peptides should only be administered under the guidance of a qualified healthcare provider.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
Community protocols most commonly describe 20–75 mcg per site-specific intramuscular injection, with 50 mcg a frequently cited middle-of-the-range starting point. These figures are community convention, not clinical evidence — no human dose-ranging study of DES IGF-1 has been conducted. The short half-life means the per-dose figure largely determines local exposure; systemic accumulation is minimal.
Frequency
Pre- or immediately post-workout IM injection into the trained muscle group is the most commonly described cadence, often on training days only. Some users rotate site-by-site across training sessions. Because of the short half-life, skipping rest days is routine in community protocols — there is no depot to carry effects forward.
Timing Considerations
Time of day
Ties to training schedule rather than clock time.
Relative to meals
Often paired with a post-workout protein-and-carbohydrate meal to ride endogenous insulin and amplify the myogenic effect.
Relative to exercise
Injected pre- or immediately post-workout, intramuscular into the trained muscle group. DES has a very short half-life and a largely local mechanism, so injection-site locality matters more than with systemic IGF-1-LR3.
Cycle Length
Typical described runs are 4–6 weeks on, followed by a comparable time off. Rationale mirrors LR3 concerns — IGF-1R signaling fatigue, theoretical mitogenic risk with chronic supraphysiologic exposure — though the localized and short-acting character of DES makes the risk argument less acute than for LR3. The 4–6 week convention is not derived from human data.
Protocol Notes
DES is supplied as a lyophilized powder reconstituted in bacteriostatic water. The practical injection target is intramuscular into the belly of the trained muscle using a small-gauge (typically 29–31g) insulin syringe; the explicit goal is local IGF-1R activation at the site of mechanical loading rather than systemic anabolism. Hypoglycemia is the dose-limiting concern and it should not be discounted on the basis of fast clearance. In the only head-to-head animal comparison, des(1-3)IGF-1 was the most potent hypoglycemic agent of five IGF-1 variants tested, LR3 included, and the low-IGFBP-affinity variants suppressed glucose over a much longer window than IGF-1 despite clearing faster. Larger doses and accidental vascular injection raise the risk further. Repeated injection into the same muscle site is a meaningful practical concern: community reports describe local scarring, fibrotic palpable changes, and occasionally sterile abscess formation when technique, rotation, and peptide purity are poor. As with LR3, the research-chemical supply chain means purity, correct peptide identity, and endotoxin content are not assured. Product that is actually native IGF-1 or LR3 mislabeled as DES is a documented market issue and changes the risk picture materially.
These numbers describe community practice, not a prescription. IGF-1 DES is not FDA-approved for any indication. Site-specific intramuscular injection carries local tissue and infection risks independent of the peptide itself. Any actual use should be under the direct supervision of a qualified healthcare provider.
Timeline of Effects
Onset
Local effects at the injection site — increased pump, fullness, reported enhanced recovery of that specific muscle — are typically described within the first 1–2 training sessions after introducing the peptide. These reports are anecdotal; no human study has objectively characterized onset.
Peak Effect
Visible local hypertrophy effects are most often described in the 3–6 week window of consistent protocol use, aligning with the typical muscle-hypertrophy adaptation timeframe rather than pharmacologic accumulation. The short half-life of DES means there is no depot peak in the conventional sense — peak local IGF-1R activation occurs within an hour of injection.
After Discontinuation
DES clears from plasma faster than IGF-1 — about fourfold faster in rats — but an antidoping study detected unchanged des(1-3)IGF-1 in rats up to 24 hours after a single intramuscular dose, so the pharmacologic tail is longer than the usual account suggests. Muscle adaptations accrued during the protocol persist under continued training and nutrition, but no subsequent injections means no subsequent supraphysiologic IGF-1R stimulation. Some users report a perceived loss of the 'full' feeling at previously targeted sites after cessation, consistent with loss of acute local IGF-1 tone.
Monitoring & Measurement
Bloodwork & Labs
- •Capillary blood glucose — the one measurement that matters acutely, given that DES was the most hypoglycemic of five IGF-1 variants in direct comparison
- •Fasting glucose and HbA1c as a baseline, particularly in anyone with impaired glucose regulation
- •Serum IGF-1, which will not detect DES on standard immunoassays but establishes where endogenous exposure sits
- •IGFBP-3, for context on the binding-protein pool the molecule is designed to escape
When to Test
Baseline before any exposure; capillary glucose around the dose itself, since the risk is acute rather than cumulative.
Interpretation & Notes
This panel is listed because glucose monitoring is the one genuinely actionable measurement for a compound with no human pharmacology, not because it makes unsupervised use safe. Two practical points. First, standard IGF-1 immunoassays are not designed to distinguish des(1-3)IGF-1 from native IGF-1, so a serum IGF-1 result cannot be read as a measure of what was injected; the assays that do identify it are mass-spectrometry methods developed for antidoping. Second, hypoglycemia with this class is not reliably brief — in pigs the low-IGFBP-affinity variants suppressed glucose over a much longer period than IGF-1 despite clearing faster, so a single reading shortly after dosing is not reassurance.
Common Questions
Why is the short half-life an advantage?
The short half-life means IGF-1 DES acts primarily at the injection site before being cleared. This allows targeted muscle growth in specific areas and reduces systemic side effects like organ growth.
Is DES IGF-1 really 10x more potent than native IGF-1?
In cultured cells, roughly yes; in a living animal, no. The review dedicated to this molecule describes it as about tenfold more potent than IGF-1 at stimulating hypertrophy and proliferation of cultured cells, and the original bovine colostrum paper called the tenfold effect of removing the N-terminal tripeptide unexpected. In vivo the figure is smaller: in dexamethasone-treated rats, des(1-3)IGF-1 was approximately 2.5-fold more potent than IGF-1 on body weight and nitrogen retention. The mechanism is the same either way — the missing Gly-Pro-Glu is the region IGF binding proteins grip, so less of the dose is sequestered and more reaches IGF-1R, with ordinary PI3K/Akt/mTOR and Ras/MAPK signalling downstream. The potency gain is specifically not receptor-driven: an early study found the truncated form about seven times more potent in a protein-synthesis bioassay with no increased ability to compete for IGF-1 binding to myoblasts.
Does DES really not bind IGF binding proteins at all?
No, and that overstatement matters. Direct biosensor measurement puts des(1-3)IGF-1 at 25-fold lower affinity for IGFBP-3 than IGF-1, moving the Kd from 0.23 nM to roughly 5.7 nM. That is substantially weaker binding and still high-affinity binding in absolute terms. There is also a species problem the popular account ignores: the near-absent binding is largely a rat finding, and in sheep, human, pig and chicken plasma the IGF-1 variants bind appreciably. Since much of the foundational DES work was done in rats, how much IGFBP escape a human would actually get is not established. A separate study found IGFBP-3 inhibited des(1-3)IGF-1-induced receptor phosphorylation over a similar concentration range to IGF-1.
How is DES IGF-1 different from IGF-1 LR3, and is DES safer?
They differ in origin and kinetics, and the safety claim usually attached to that difference is wrong. LR3 is an engineered analogue — an arginine substitution at position 3 plus a 13-residue N-terminal extension — built for a long systemic half-life. DES is a naturally occurring truncation that clears faster; in rats its plasma clearance was 4.59 mL/min per kg against 1.20 for IGF-1. People infer from that faster clearance that DES carries less hypoglycaemia risk than LR3. The only study that compared them directly found the reverse: in pigs given IGF-1, long-IGF-1, R3IGF-1, LR3IGF-1 and des(1-3)IGF-1, hypoglycaemic potency rose in that order, placing DES highest, and all the low-IGFBP-affinity variants produced four- to eight-fold greater cumulative glucose suppression over four hours than IGF-1 did. The authors put it plainly: despite more rapid clearance, these variants show proportionately superior potency for sustained hypoglycaemic action. Treat DES as at least as hypoglycaemic as LR3, not less.
Does site-injecting DES grow the muscle you inject it into?
No human study has ever tested it, and the animal evidence points elsewhere. The rationale is reasonable — a short-lived IGF-1R agonist injected into a loaded muscle should drive local Akt and mTOR signalling, and in mice des IGF-1 does increase Akt-1 phosphorylation at Ser473 in skeletal and cardiac muscle, with the p70 S6K response present in young animals and absent in aged ones. But the same mouse experiment recorded a roughly 50% fall in plasma glucose, which is a systemic effect by definition and sits awkwardly with the local-only framing. The review dedicated to des(1-3)IGF-1 notes that its retained in-vivo potency produces selective anabolic effects particularly evident in gut tissues rather than muscle. No human imaging study has compared injected with non-injected muscles, so the differential-hypertrophy claim at the centre of this product is mechanism and anecdote.
Who IGF-1 DES Is NOT For
- •Active or recent-history cancer, particularly hormone-sensitive malignancies — localized administration does not eliminate the IGF-1R activation concern, and any residual systemic exposure still carries mitogenic risk.
- •Diabetes or impaired glucose regulation — even with the short half-life, acute glucose lowering can occur at higher doses and compound insulin or secretagogue effects.
- •Pregnancy and breastfeeding — no safety data; IGF-1 is central to fetal growth regulation.
- •Pediatric use (under 18) — no appropriate indication, and growth-plate and developmental considerations apply.
- •Active acromegaly or untreated pituitary tumor — any exogenous IGF-1R agonism is contraindicated.
- •Local injection-site contraindications — active infection, significant scar tissue, or bleeding disorder at the planned injection site.
Drug & Supplement Interactions
Interaction data specific to DES is absent; extrapolation from IGF-1 pharmacology applies in muted form given the short systemic half-life. Insulin, sulfonylureas, meglitinides, and other glucose-lowering agents remain the most clinically meaningful interaction, and the usual reassurance that DES carries a narrower risk window than LR3 does not survive the evidence. In pigs, hypoglycemic potency ranked des(1-3)IGF-1 above LR3IGF-1, and the whole low-IGFBP-affinity class produced four- to eight-fold greater cumulative glucose suppression than IGF-1 over four hours. Patients on diabetes medications should not use DES at all without clinician oversight. Concurrent use with growth hormone, GH secretagogues (tesamorelin, sermorelin, CJC-1295, ipamorelin), or MK-677 potentiates systemic IGF-1R activation beyond what DES alone produces, eroding any claimed 'localized' risk advantage. Anabolic-androgenic steroids do not directly interact with IGF-1R but share the cardiovascular- and cancer-risk profile. Oncology patients — particularly those on IGF-1R-targeting agents — should not use DES. Corticosteroids may blunt local anabolic response.
Safety Profile
Common Side Effects
Cautions
- • Not FDA-approved
- • Very limited human safety data
- • Theoretical cancer risk
- • Must be injected site-specifically
What We Don't Know
The human safety profile is not poorly characterized so much as absent: no clinical trial, no pharmacokinetic study, no systematic surveillance of any kind. Everything on this page is extrapolated from rodent, porcine and primate work mostly performed in the 1990s, and the species caveat is not cosmetic — the IGFBP escape that defines the molecule is most extreme in the rat, which is where most of the foundational work was done. Long-term consequences of repeated supraphysiologic IGF-1R activation in muscle, and the oncological implications of episodic rather than chronic exposure, are entirely uncharacterized.
Legal Status
United States
IGF-1 DES is not FDA-approved for any medical indication. It sits in the same regulatory category as LR3: a non-approved analogue distinct from mecasermin (Increlex), sold through research-chemical channels labeled 'not for human use.' Distribution for human consumption is unauthorized under the FD&C Act. It is not a scheduled controlled substance.
International
Not authorized as a medicine in the EU, UK, Canada, or Australia. Australian TGA treats it as a Schedule 4 prescription-only substance. Importation for personal use is restricted or prohibited in most developed regulatory regimes.
Sports & Competition
Prohibited at all times under WADA category S2.3 (growth factors and growth factor modulators), which explicitly names insulin-like growth factor 1 (IGF-1, mecasermin) and its analogues. Des(1-3)IGF-1 is an IGF-1 analogue and is covered by that entry; all S2 substances are non-Specified. Athletes subject to WADA, USADA, UKAD or equivalent frameworks should consider DES categorically prohibited in and out of competition, and site-specific intramuscular injection does not change its status. Validated mass-spectrometry methods for detecting des(1-3)IGF-1 in biological samples have been published specifically for antidoping purposes, and in rats unchanged DES was detectable up to 24 hours after a single intramuscular dose.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
IGF-1 DES only works locally, so it carries no systemic risk.
Reality
There is a direct measurement against this. When des IGF-1 was given to mice, plasma glucose fell by roughly 50% — an unambiguously systemic effect — even as plasma insulin and IGF-1 were unchanged. Faster clearance reduces the duration of systemic exposure relative to LR3; it does not confine the drug to the injection site. And the review dedicated to des(1-3)IGF-1 notes its in-vivo anabolic effects are most evident in gut tissue, which is about as far from a local muscle effect as the data could point.
Myth
Site-injection DES builds muscle where you inject it, like a targeted spot-grower.
Reality
There is a plausible mechanistic basis for enhanced local satellite cell activation at the injection site, but robust human imaging evidence of differential hypertrophy between injected and non-injected muscles is not established. Hypertrophy still requires training, mechanical load, and systemic nutrition; the peptide does not override those requirements.
Myth
Because DES is naturally occurring in the body, it is safer than LR3.
Reality
DES is found endogenously at trace concentrations in specific tissues — it was isolated from bovine colostrum and from human fetal and adult brain. Injecting tens of micrograms into a muscle produces a supraphysiologic local concentration not seen in normal physiology. Naturally occurring at nanogram levels is not the same as naturally occurring at the doses used in injection protocols, and on the one comparison that exists DES is the most hypoglycemic member of its family rather than the gentlest.
Myth
DES clears quickly, so it carries less hypoglycemia risk than LR3.
Reality
This is the most consequential error in circulation about this peptide, and it is backwards. The one study that compared the IGF-1 variants head to head, in pigs, ranked acute hypoglycemic potency as IGF-1 < long-IGF-1 < R3IGF-1 approximately LR3IGF-1 < des(1-3)IGF-1 — DES was the most potent of the five. The variants as a class also suppressed glucose far longer than IGF-1, producing four- to eight-fold greater cumulative hypoglycemia over four hours, and the authors concluded that despite more rapid clearance from the circulation these variants show proportionately superior potency for sustained hypoglycemic action. Rapid plasma clearance and brief glucose lowering are not the same thing. Anyone using DES should treat hypoglycemia risk as at least equal to LR3.
Myth
'(1-3)IGF-1' and 'des-(1-3)IGF-1' are the same molecule with a shorter name.
Reality
They are opposite molecules. Des-(1-3)IGF-1 is IGF-1 with the first three N-terminal amino acids removed — the muscle-growth peptide sold as DES. '(1-3)IGF-1' — sometimes written GPE or glypromate — refers to just the tripeptide Gly-Pro-Glu, which is the fragment that gets cleaved off during DES formation and has its own neuroactive properties studied in Gluckman-lineage neuroscience. Some 2026 literature (e.g., Brain Behav 2026) uses '(1-3)IGF-1' to denote the tripeptide, so buyers and readers should confirm from a paper's methods or mechanism which molecule is actually being described before generalizing findings to DES.
Published Research
23 studiesDetection of LongR3-IGF-I, Des(1-3)-IGF-I, and R3-IGF-I using immunopurification and high resolution mass spectrometry for antidoping purposes
The most directly relevant modern paper, and the only one that engages with how this compound is actually used. It states that IGF-1 and its analogues LongR3, Des(1-3) and R3 are prohibited substances in sport, were never approved for human use, and are readily available as black market products for bodybuilding. Two findings matter here: analysis of black market products found abundant signs of lower quality and oxidised peptide forms, and after a single intramuscular dose in rats unchanged Des(1-3)-IGF-I remained detectable for 24 hours while LongR3 disappeared after 4 — which is the opposite of the kinetics the community account assumes.
Age-related differences in the des IGF-I-mediated activation of Akt-1 and p70 S6K in mouse skeletal muscle
Des(1-3)IGF-1 treatment normalizes type 1 IGF receptor and phospho-Akt (Thr 308) immunoreactivity in predegenerative retina of diabetic rats
Differential effects of des IGF-1 on Erks, AKT-1 and P70 S6K activation in mouse skeletal and cardiac muscle
Effect of IGFBP-3 on IGF- and IGF-analogue-induced insulin-like growth factor-I receptor (IGFIR) signalling
IGF-I variants which bind poorly to IGF-binding proteins show more potent and prolonged hypoglycaemic action than native IGF-I in pigs and marmoset monkeys
The most safety-relevant paper on this page, and the one that overturns the usual DES-versus-LR3 claim. In pigs given five IGF-1 variants, acute hypoglycaemic potency ran IGF-1 < long-IGF-1 < R3IGF-1 approximately LR3IGF-1 < des(1-3)IGF-1 — DES the most potent of the five — and the variants suppressed glucose over a much longer period than IGF-1, with a four- to eight-fold greater cumulative effect over four hours. The authors state that despite their more rapid clearance from the circulation, variants with lower IGFBP affinity show proportionately superior potency for sustained hypoglycaemic action. The inference that faster clearance makes DES the gentler option on blood glucose is exactly backwards.
IGF-I has a dual effect on insulin release from isolated, perifused adult rat islets of Langerhans
Des(1-3)IGF-I: a truncated form of insulin-like growth factor-I
The only review devoted to this molecule, and the best single source on it. It establishes the origins — isolated from bovine colostrum, human brain and porcine uterus, probably from post-translational cleavage of IGF-1 — and states the potency claim with the qualifier the marketing drops: about tenfold more potent than IGF-1 at stimulating hypertrophy and proliferation of cultured cells, a consequence of much reduced IGFBP binding, with the increased potency retained only in part in vivo and the selective anabolic effects particularly evident in gut tissues. It also notes that clinical opportunities had not been evaluated, which thirty years later remains true.
Biosensor measurement of the binding of insulin-like growth factors I and II and their analogues to the insulin-like growth factor-binding protein-3
The effects of insulin-like growth factor (IGF)-1, IGF-2, and des-IGF-1 on neuronal loss after hypoxic-ischemic brain injury in adult rats: evidence for a role for IGF binding proteins
Effects of IGF-1, truncated IGF-1 and the tripeptide Gly-Pro-Glu on acetylcholine release from parietal cortex of rat brain
Differences in the association of insulin-like growth factor-I (IGF-I) and IGF-I variants with rat, sheep, pig, human and chicken plasma-binding proteins
Isolation and characterization of variant IGF-1 as well as IGF-2 from adult human brain
Characterization of somatomedins from human fetal brain: identification of a variant form of insulin-like growth factor I
Insulin-like growth factors 1 and 2 in bovine colostrum. Sequences and biological activities compared with those of a potent truncated form
The isolation paper, and the origin of the tenfold figure. IGF-1, IGF-2 and a truncated IGF-1 were purified to homogeneity from bovine colostrum and fully sequenced, with the variant shown to lack the N-terminal tripeptide Gly-Pro-Glu. The authors describe the approximately tenfold effect on biological activity of removing that tripeptide as unexpected — which is where the number everyone quotes comes from, measured in L6 rat myoblasts rather than in an animal.
Natural and synthetic forms of insulin-like growth factor-1 (IGF-1) and the potent derivative, destripeptide IGF-1: biological activities and receptor binding
The experiment that shows why DES is more potent, and it is not the reason most descriptions give. The destripeptide derivative was roughly seven times more potent than IGF-1 in a protein-synthesis bioassay, yet showed no increased ability to compete for IGF-1 binding to L6 myoblasts. The receptor has no preference for DES; the advantage is entirely that more of it escapes the binding proteins and arrives.
A key functional role for the insulin-like growth factor 1 N-terminal pentapeptide
Identification of Gly-Pro-Glu (GPE), the aminoterminal tripeptide of insulin-like growth factor 1 which is truncated in brain, as a novel neuroactive peptide
Insulin-like growth factor (IGF)-binding proteins inhibit the biological activities of IGF-1 and IGF-2 but not des-(1-3)-IGF-1
Truncated IGF-1 exerts trophic effects on fetal brain tissue grafts
Plasma clearance and tissue distribution of labelled insulin-like growth factor-I (IGF-I), IGF-II and des(1-3)IGF-I in rats
Increased weight gain, nitrogen retention and muscle protein synthesis following treatment of diabetic rats with insulin-like growth factor-I and des(1-3)IGF-I
Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated rats
Quick Facts
- Class
- Growth Factor Analogue
- Tier
- D
- Evidence
- Emerging
- Safety
- Limited Data
- Updated
- Nov 2026
- Citations
- 23PubMed
Also known as
Tags
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.